Arena Pharmaceuticals, Inc.  

(Public, NASDAQ:ARNA)   Watch this stock  
Find more results for arna
+0.05 (3.52%)
Feb 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.43 - 1.50
52 week 1.34 - 2.16
Open 1.50
Vol / Avg. 886,668.00/1.70M
Mkt cap 370.27M
P/E     -
Div/yield     -
EPS -0.38
Shares 243.31M
Beta -0.64
Inst. own 47%
Feb 27, 2017
Q4 2016 Arena Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Jan 12, 2017
Arena Pharmaceuticals Inc at JPMorgan Healthcare Conference
Nov 29, 2016
Arena Pharmaceuticals Inc at Piper Jaffray Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin -64.85% -281.74%
Operating margin -51.23% -269.26%
EBITD margin - -232.70%
Return on average assets -23.38% -40.50%
Return on average equity -587.01% -214.06%
Employees 228 -
CDP Score - -


6154 Nancy Ridge Dr
SAN DIEGO, CA 92121-3223
United States - Map
+1-858-4537200 (Phone)
+1-858-4537210 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Arena Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing small molecule drugs across a range of therapeutic areas. The Company has three primary investigational clinical programs: etrasimod (APD334) in Phase II evaluation for ulcerative colitis, APD371 entering Phase II evaluation for the treatment of pain associated with Crohn's disease, and ralinepag (APD811) in Phase II evaluation for pulmonary arterial hypertension (PAH). The Company's drug, Lorcaserin, is approved for marketing in the United States and South Korea for the indication of weight management. The Company's drug candidates in clinical development include APD334 for autoimmune diseases, ralinepag for vascular diseases and APD371 for pain. The Company's programs under collaboration include nelotanserin for dementia-associated psychosis, temanogrel for thrombotic diseases, and an undisclosed orphan GPCR for central nervous system (CNS) indication(s).

Officers and directors

Amit D. Munshi President, Chief Executive Officer, Director
Age: 48
Bio & Compensation  - Reuters
Kevin R. Lind Chief Financial Officer, Principal Financial Officer, Executive Vice President, Principal Accounting Officer
Age: 40
Bio & Compensation  - Reuters
Steven W. Spector J.D. Executive Vice President, General Counsel, Secretary
Age: 51
Bio & Compensation  - Reuters
Vincent E. Aurentz Executive Vice President and Chief Business Officer
Bio & Compensation  - Reuters
Maurice J. Mezzino Senior Vice President - Corporate Development
Age: 61
Bio & Compensation  - Reuters
Tina Susan Nova Ph.D. Lead Independent Director
Age: 62
Bio & Compensation  - Reuters
Donald D. Belcher Director
Age: 77
Bio & Compensation  - Reuters
Jayson Dallas M.D. Director
Age: 48
Bio & Compensation  - Reuters
Oliver S. Fetzer Ph.D. Director
Age: 53
Bio & Compensation  - Reuters
Harry F. Hixson Jr., Ph.D. Director
Age: 78
Bio & Compensation  - Reuters